fr   en
Fundraisings
Select a company :
Select an investor :
Choose date:
1   |   2   |   3   |   4   |   5   |   6   |   7   |   8   |   9   |   10   |   11      »      [23]
Date Company Amount Investors Planned use / Other
2010-09-08 Arcarios (Belgium) Tigenix (Belgium) €4.1 million BioGeneration Ventures.
Erasmus MC Biomedical Fund (The Netherlands)
Gemma Frisius Fund (Belgium)
CD3 (Belgium)
Baekeland Fund II (Belgium)
LRM (Belgium)
Credit Agricole (France)
VINNOF (Belgium)
See details
2010-09-08 Addex Pharmaceuticals (Switzerland) $900,000 The Michael J. Fox Foundation (USA) See details
2010-09-03 Lumavita (Switzerland) 11m (€8m)   See details
2010-09-03 Forbion Capital Partners (The Netherlands) €190 million   See details
2010-09-03 Lumavita (Switzerland) 11m (€8m)   See details
2010-07-26 Vivalis (France) €30,3 million Groupe Grimaud La Corbière subscribed to this rights issue for an aggregate value of €15.7 million, through the exercise of the totality of its subscription rights. GLC will now hold a 51.9% stake in Vivalis. See details
2010-07-26 Cerenis Therapeutics (France) € 40 million French Strategic Investment Fund (FSI - Fonds Stratégique d’Investissement)
Sofinnova Partners (France)
HealthCap (Sweden)
Alta Partners (France)
TVM Capital (Germany)
EDF Ventures (USA)
OrbiMed (USA)
DAIWA Corporate Investment (Japan)
See details
2010-07-26 Cerenis Therapeutics (France) Groupe Novasep (France) €10.7 million OSEO (France)
See details
2010-07-26 Vivalis (France) €30,3 million Groupe Grimaud La Corbière subscribed to this rights issue for an aggregate value of €15.7 million, through the exercise of the totality of its subscription rights. GLC will now hold a 51.9% stake in Vivalis. See details
2010-07-21 Novagali Pharma (France) €22 million Several existing shareholders (Edmond de Rothschild Investment Partners, IDInvest Partners, Auriga Partners, FCJE, Siparex/Sigefi, 123 Venture and Bernard Chauvin) have made purchase commitments totalling over € 9 m. See details
2010-06-29 AB Science (France) Bull (France) Genomic Vision (France) SkuldTech (France) €10 million (€6.2m to AB Science, €2m to Bull, €0.7 m to Genomic Vision and €0.3m to SkuldTech) OSEO (France) See details
2010-06-17 Ipsogen (France) € 1.9 million historical shareholders and new investors See details
2010-06-11 Mologen (Germany) € 4.3 million institutional investors See details
2010-06-07 Molmed (Italy) € 1.4 million Regione Lombardia (Italy) See details
2010-06-07 Cytheris (France) € 12 million CDC Entreprises (France), acting for the Strategic Investment Fund (FSI)
Bioam Gestion (France)
Caisse de dépôt et Placement du Québec (Canada)
CDC Innovation (France)
Crédit Agricole Private Equity (France)
Forbion Capital Partners (The Netherlands).
See details
1   |   2   |   3   |   4   |   5   |   6   |   7   |   8   |   9   |   10   |   11      »      [23]